Innate Pharma SA has received a $5 million milestone payment from Bristol-Myers Squibb as part of the lirilumab licensing agreement. This payment was triggered by the dosing of a first patient in a Phase II trial of lirilumab in combination with rituximab in patients with relapsed/refractory or high-risk untreated chronic lymphocytic leukemia. Herve Brailly, chief executive officer and co-founder of Innate Pharma, said, “This milestone marks the start of a new Phase II trial of liril...